StockStory.org on MSN3d
Vertex Pharmaceuticals’s (NASDAQ:VRTX) Q4 Sales Top EstimatesBiotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q4 CY2024 results , with sales up 15.7% year on year to $2.91 ...
Morgan Stanley analyst Terence Flynn raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $459 from $450 and keeps an Equal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback